IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1013
Positioning
Market Dominance
Manufacturing
Medical Equipment
$305M
William M. Greenman
Cerus Corporation focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America and internationally.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = CERS ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$CERS CERUS CORP | 57 | 58 | 53 | 78 | - | 93.6x | -26.3% | -7.6% | 47.0% | -7.0% | -12.5% | 18.5% | 0.0% | 246.0x | $305M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
CERUS CORP (CERS) receives a "Hold" rating with a composite score of 57.1/100. It ranks #1013 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
William M. Greenman
Chief Executive Officer
Labor Force
290
58
35
50
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for CERS
Outperforming peers — winners tend to keep winning over 3-12 months
Fair valuation relative to peers
Average quality profile
Average volatility — neutral timing signal
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for CERS.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 58 | 51 | +7ALPHA |
| MOMENTUM | 78 | 81 | -3NEUTRAL |
| VALUATION | 53 | 32 | +21ALPHA |
| INVESTMENT | 35 | 58 | -23DRAG |
| STABILITY | 50 | 34 | +16ALPHA |
| SHORT INT | 44 | 39 | +5NEUTRAL |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC 1.4% vs WACC 8.5% (spread -7.1%)
GM 47% vs sector 43%, OM -7% vs sector 1%
Capital turnover 0.52x
Rev growth 19%, 10yr history
Interest coverage 0.6x, Net debt/EBITDA 56.0x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our model assigns CERUS CORP a Hold rating, with a composite score of 57.1/100 and 3 out of 5 stars. Ranked #1013 of 7,333 stocks, CERS presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
With a quality score of 58/100, CERS shows adequate but unremarkable business quality. The company reports a return on equity of -26.3% (sector avg: -2.5%), gross margins of 47.0% (sector avg: 42.5%), net margins of -12.5% (sector avg: -0.2%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
CERS's value score of 53/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include an EV/EBITDA of 93.63x, a P/B ratio of 7.44x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
CERUS CORP's investment score of 35/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 18.5% vs. a sector average of 5.9% and a return on assets of -7.6% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
CERS shows strong momentum characteristics with a score of 78/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth stands at 18.5% year-over-year, while a beta of 1.57 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
With a stability score of 50/100, CERS exhibits average financial resilience. Key stability metrics include a beta of 1.57 and a debt-to-equity ratio of 246.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
The short interest score of 44/100 for CERS suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include high market sensitivity (beta: 1.57), elevated leverage (D/E: 246.00x), small-cap liquidity risk. With a $305M market cap (small-cap), CERUS CORP may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
CERUS CORP is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #1013 of 7,333 overall (86th percentile). Key comparisons include ROE of -26.3% trailing the -2.5% sector median and operating margins of -7.0% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While CERS currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Momentum (78) vs Investment (35) — closing this gap could shift the rating.
EV/EBITDA 717% ABOVE SECTOR MEDIAN
ROE 962% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 11% ABOVE SECTOR MEDIAN (FAVORABLE)
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate CERUS CORP (CERS) as a Hold with a composite score of 57.1/100 at a current price of $2.39. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling for existing holders. Our factors are split, and the overall profile suggests patience is warranted.
The rating is primarily driven by strength in momentum (78th percentile) and quality (58th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (35th percentile) and stability (50th percentile) tempers our overall conviction. We assign a No Moat rating (35/100), Very High uncertainty, and Poor capital allocation.
Key items to watch: balance sheet deleveraging progress; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
CERUS CORP holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 57.1/100 places it at rank #1013 in our full 7,333-stock universe. At $305M in market capitalization, CERUS CORP is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
The near-term outlook is constructive, with revenue growing at 19% and momentum in the 78th percentile confirming positive market sentiment and institutional accumulation. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy. Investment factor at the 35th percentile indicates reinvestment patterns that investors should monitor for sustainability.
The margin cascade tells an important story: gross margins of 47% (+4.5pp vs sector) narrow to operating margins of -7% (-8.3pp vs sector) and net margins of -12.5%, yielding a gross-to-net conversion rate of -27%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $2.39, CERUS CORP is trading near fair value based on current fundamentals. Our value factor score of 53/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at EV/EBITDA of 93.6x (at a premium), P/B of 7.4x, P/S of 3.5x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 47% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Revenue growth of 19% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
Positive momentum (78th percentile) indicates institutional accumulation and favorable technical dynamics that tend to persist in the intermediate term.
Elevated leverage (246% D/E) amplifies downside risk and limits management's financial flexibility in adverse scenarios.
Thin net margins of -12.5% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a Very High uncertainty rating to CERUS CORP. The stock exhibits multiple compounding risk factors: elevated market sensitivity (beta of 1.57), significant leverage (246% debt-to-equity), current negative profitability (net margin -12.5%). The extreme uncertainty around future cash flows makes precise valuation difficult, and the range of outcomes is exceptionally wide. Only investors with high risk tolerance and extended time horizons should consider this name.
Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 1.57); significant leverage (246% debt-to-equity); current negative profitability (net margin -12.5%); the combination of leverage (246% D/E) and thin margins (-12.5% net) amplifies downside risk. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 50th percentile and quality factor at the 58th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 47% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate CERUS CORP's capital allocation as Poor. Key concerns include low returns on equity (-26.3%), elevated leverage (246% D/E), negative profitability, weak asset returns (ROA -7.6%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — CERUS CORP significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, CERUS CORP receives a Hold rating with a composite score of 57.1/100 (rank #1013 of 7,333). Our quantitative framework assigns a No Moat (35/100, trend: stable), Very High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 55/100.
Our analysis supports a neutral stance on CERUS CORP. While the quantitative profile is not weak enough to warrant selling, it lacks the multi-factor strength required for a buy recommendation. Existing holders should maintain positions and monitor for catalysts — either fundamental improvement or valuation compression — that would shift the risk-reward balance.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign CERUS CORP a meaningful economic moat, scoring 35/100 on our composite assessment. The ROIC-WACC spread of -7.1% is the primary signal of economic value creation. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, growth durability, reached only 17.3/20.
The strongest moat sources are growth durability (17.3/20) and margin superiority (11/20). Rev growth 19%, 10yr history. GM 47% vs sector 43%, OM -7% vs sector 1%. These pillars form the core of CERUS CORP's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and financial resilience (0/20). Capital turnover 0.52x. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect CERUS CORP's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 47% providing a solid profitability foundation, robust top-line growth of 19% expanding the revenue base. The margin cascade from 47% gross to -7% operating to -12.5% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality is adequate though not exceptional, with the quality factor at the 58th percentile.
The margin profile shows gross margins of 47%, operating margins of -7%, net margins of -12.5%. Return metrics include ROE of -26.3% and ROA of -7.6%. Relative to the Manufacturing sector, gross margins are 4.5 percentage points above the sector median of 43%, and ROE of -26.3% compares to a sector median of -2.5%.
The balance sheet reflects high leverage with D/E of 246%, which may limit financial flexibility, revenue growth of 19%. The sector median D/E is 0%, putting CERUS CORP at higher leverage than the typical peer. Elevated leverage in combination with the current margin profile warrants close monitoring for any deterioration in debt-servicing capacity.
High beta of 1.57 means amplified losses in market selloffs — in a broad market correction, this stock would likely decline more than the index.
Cerus Corporation shareholders have experienced an 80% loss over the past five years and a 20% loss in the last year, despite the company's revenue growing by 16% annually during the five-year period. The market appears concerned about when the company, which is currently operating at a loss, will become profitable. Investors are advised to examine the balance sheet strength and consider potential risks before investing.

TD Cowen has reiterated its Buy rating and $5.00 price target for Cerus (NASDAQ:CERS) after the company reported strong preliminary fourth-quarter product revenue of $57.8 million, exceeding consensus estimates, and provided optimistic 2026 revenue guidance. The firm's $5.00 price target represents a significant upside from the current price, aligning with a bullish analyst consensus. Cerus's recent performance is also bolstered by a new group purchasing agreement with Blood Centers of America, expanding its market reach.

TD Cowen sees long-term value in Cerus Corporation (CERS), citing its Intercept Fibrinogen Complex franchise as an "underappreciated" growth engine and a new partnership with Blood Centers of America as a significant booster for adoption and scalability. The firm maintains a 'Buy' rating with a $5 price target, projecting a 143% upside, based on the company's sustainable double-digit revenue growth and appealing valuation. Cerus, a biomedical products company specializing in the INTERCEPT Blood System, recently finalized a purchasing agreement with BCA for its full INTERCEPT product offering.

Cerus Corporation announced a group purchasing agreement with Blood Centers of America (BCA) to expand access to its INTERCEPT product line for pathogen reduction technology. This partnership aims to increase the availability of safer blood products, including pathogen-reduced platelets and INTERCEPT Fibrinogen Complex, across BCA's network of blood centers and their hospital customers. The agreement is expected to facilitate easier distribution and adoption of these critical blood safety technologies.

Cerus Corporation (NASDAQ:CERS) reported its Q3 2025 earnings, showcasing record product revenue of $52.7 million, a 15% year-over-year increase, and achieving its sixth consecutive quarter of positive non-GAAP adjusted EBITDA. The company also raised its full-year 2025 product revenue guidance and discussed the ongoing shift in IFC sales to a kit-based model, which is expected to improve gross margins and leverage existing blood center sales channels. Key updates included continued progress in INTERCEPT adoption, particularly in the US and EMEA, and advancements in its development pipeline with the completion of enrollment in the U.S. Phase III RedeS trial.
Above 50MA
37.18%
Net New Highs
+51081